Kilitch Drugs (India) Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6
Kilitch Drugs (India) heeft een totaal eigen vermogen van ₹1.9B en een totale schuld van ₹324.1M, wat de schuld-eigenvermogensverhouding op 17.2% brengt. De totale activa en totale passiva bedragen respectievelijk ₹2.6B en ₹709.5M. De EBIT Kilitch Drugs (India) is ₹154.0M waardoor de rentedekking 3.4 is. Het heeft contanten en kortetermijnbeleggingen van ₹588.5M.
Belangrijke informatie
17.2%
Verhouding schuld/eigen vermogen
₹324.12m
Schuld
| Rente dekkingsratio | 3.4x |
| Contant | ₹588.52m |
| Aandelen | ₹1.88b |
| Totaal verplichtingen | ₹709.50m |
| Totaal activa | ₹2.59b |
Recente financiële gezondheidsupdates
Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly
Mar 05
These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Sep 08Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt
Jul 06These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Dec 17Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?
Mar 21Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?
Dec 03
Recent updates
Kilitch Drugs (India) Limited (NSE:KILITCH) Not Flying Under The Radar
Jul 23Here's Why Kilitch Drugs (India) (NSE:KILITCH) Can Manage Its Debt Responsibly
Mar 05Kilitch Drugs (India) Limited (NSE:KILITCH) Looks Just Right With A 26% Price Jump
Feb 02We Ran A Stock Scan For Earnings Growth And Kilitch Drugs (India) (NSE:KILITCH) Passed With Ease
Jan 30Investors Shouldn't Be Too Comfortable With Kilitch Drugs (India)'s (NSE:KILITCH) Earnings
Nov 17Shareholders Would Not Be Objecting To Kilitch Drugs (India) Limited's (NSE:KILITCH) CEO Compensation And Here's Why
Sep 23These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Sep 08Here's Why Kilitch Drugs (India) (NSE:KILITCH) Has Caught The Eye Of Investors
May 05Kilitch Drugs (India) (NSE:KILITCH) Could Easily Take On More Debt
Jul 06Here's Why I Think Kilitch Drugs (India) (NSE:KILITCH) Might Deserve Your Attention Today
Apr 08These 4 Measures Indicate That Kilitch Drugs (India) (NSE:KILITCH) Is Using Debt Reasonably Well
Dec 17Is Kilitch Drugs (India) (NSE:KILITCH) Using Too Much Debt?
Mar 21Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Feb 13Is Kilitch Drugs (India) (NSE:KILITCH) Weighed On By Its Debt Load?
Dec 03Does Kilitch Drugs (India) Limited (NSE:KILITCH) Have A Place In Your Dividend Stock Portfolio?
Aug 20Should Weakness in Kilitch Drugs (India) Limited's (NSE:KILITCH) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jul 16Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( ₹1.5B ) KILITCH } overtreffen de korte termijn passiva ( ₹707.8M ).
Langlopende schulden: De kortetermijnactiva KILITCH ( ₹1.5B ) overtreffen de langetermijnschulden ( ₹1.7M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: KILITCH heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van KILITCH is de afgelopen 5 jaar gestegen van 10.9% naar 17.2%.
Schuldendekking: De schuld van KILITCH wordt goed gedekt door de operationele kasstroom ( 64.9% ).
Rentedekking: De rentebetalingen op de schuld van KILITCH worden goed gedekt door EBIT ( 3.4 x dekking).